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SLEEP DURATION/SLEEP QUALITY
Bisphenol-A and Sleep Adequacy among Adults in the National Health and 
Nutrition Examination Surveys
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Research Program, Baltimore, MD; 3Department of Community & Environmental Health, Old Dominion University, Norfolk, VA; 4Department of Medicine, Johns Hopkins 
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Study Objectives: To evaluate bisphenol-A (BPA) level and its relationship to sleep adequacy in a nationally representative sample of U.S. adults.
Methods: A population-based cross-sectional study was conducted using 2005–2010 National Health and Nutrition Examination Survey whereby data 
were collected using in-person interviews, physical examination and laboratory testing. BPA level was measured in urine samples and analyzed as 
loge-transformed variable and in quartiles (< 0.9 ng/mL; 0.9 to < 1.9 ng/mL; 1.9 to < 3.7 ng/mL; 3.7+ ng/mL). Sleep adequacy was operationalized with three 
questions: “How much sleep do you usually get at night on weekdays or workdays?”, “Have you ever told a doctor or other health professionals that you 
have trouble sleeping?” and “Have you ever been told by a doctor or other health professional that you have a sleep disorder?” Sleep duration was further 
categorized as (< 6 h, ≥ 6 h ); (< 7 h, 7–8 h, > 8 h ); (< 5 h, 5–6 h, 7–8 h, ≥ 9 h ). Linear, binary, and ordinal logistic regression models were constructed.
Results: Loge-transformed BPA level was inversely related to sleep duration defined, in hours, as a continuous variable, a dichotomous variable (≥ 6, < 6 ), or 
an ordinal variable (≥ 9, 7–8, 5–6, < 5 ), after adjustment for confounders. Help-seeking behavior for sleep problems and diagnosis with sleep disorders were 
not significantly associated with loge-transformed BPA level in fully adjusted models.
Conclusions: Loge-transformed BPA level may be associated with fewer hours of sleep among U.S. adults, with implications for prevention. Further research 
involving diverse populations are needed to confirm these study findings.
Keywords: bisphenol-A, endocrine disruptor, sleep duration, sleep disorder, survey
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INTRODUCTION
Growing evidence has implicated sleep as a key player in the 
regulation of appetite, metabolic and immune functions.1 In 
recent studies, suboptimal sleep duration has been linked to 
serious health problems, including obesity, insulin resistance, 
type 2 diabetes, hypertension, metabolic syndrome, cardiovas-
cular disease, and cancer.2–41 Sleep disorders, described as dif-
ficulty initiating or maintaining sleep or non-restorative sleep, 
are highly prevalent and often under-diagnosed in the U.S.42,43 
In particular, 10% to 15% of U.S. adults are affected by in-
somnia.44 Also, 3% to 7% of men and 2% to 5% of women have 
diagnoses of obstructive sleep apnea (OSA), whereas 82% of 
men and 93% of women with moderate to severe OSA may be 
undiagnosed.45
Identification of modifiable risk/protective factors for inad-
equate sleep is a prerequisite for the design, implementation, 
and evaluation of preventive strategies aimed at reducing its 
health impact. Whereas dietary habits46,47 and sedentary life-
style48–54 have recently been correlated with sleep, little re-
search has been done on endocrine disruptors. Bisphenol-A 
(BPA) is a carbon-based synthetic compound used in the manu-
facturing of polycarbonate plastics, epoxy resins, and food and 
beverage containers.55–59 It is a ubiquitous endocrine disruptor 
with estrogenic activity and is known to exert a wide variety of 
metabolic effects leading to reproductive and thyroid hormone 
dysregulation, weight gain, glucose intolerance, insulin resis-
tance, type 2 diabetes, metabolic syndrome, cardiovascular 
disease, and fatty liver disease.60–69 Recent literature reviews 
have pointed out the heterogeneity of epidemiologic evidence 
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Significance
Among U.S. adults who participated in the 2005–2010 National Health and Nutrition Examination Surveys, an inverse relationship may exist between 
urinary loge-transformed bisphenol-A level and sleep duration, but not with diagnosis or treatment for sleep problems.
linking BPA exposure to various health outcomes, rendering 
the magnitude of the association difficult to estimate via meta-
analyses.70–72 BPA may impact suboptimal sleep and sleep dis-
orders indirectly via its potential role in cardiometabolic risk 
factors and health problems.60–69 A direct impact of BPA on the 
muscle function in the upper airway leading to OSA has also 
been suggested based on analogous findings from biomedical 
research.73 Although the link between BPA and sleep appears 
to be biologically plausible, to date, only one study has corre-
lated sleep issues with high levels of BPA.73
The aim of this cross-sectional study is to evaluate level 
of BPA and its relationship to sleep adequacy (sleep dura-
tion, help-seeking behavior for sleep problems, and diagnosis 
with sleep disorders) in a nationally representative sample of 
U.S. adults, by performing secondary analyses using 2005–
2010 National Health and Nutrition Examination Surveys 
(NHANES) data. We hypothesize that BPA level is inversely 
related to sleep duration and has a negative impact on sleep 
problems and disorders.
METHODS
National Health and Nutrition Examination Surveys 2005–2010
The NHANES is a program of studies conducted by the Na-
tional Center for Health Statistics, a division of the Centers 
for Disease Control and Prevention (CDC), to assess the health 
and nutritional status of U.S. children and adults and to deter-
mine the prevalence of major diseases and their risk factors.74,75 
The NHANES uses stratified multistage cluster sampling with 
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oversampling of African Americans, Asians, Hispanics and 
adults 60 years and older.74 Demographic, socioeconomic, and 
nutritional data were collected through in-person interviews, 
physical examinations and laboratory tests.74,75
Study Participants
Since 1999, NHANES has become a continuous surveillance 
system. We selected 31,034 NHANES participants from three 
consecutive waves, namely, 2005–2006 (n = 10,348), 2007–
2008 (n = 10,149), and 2009–2010 (n = 10,537).We excluded 
pregnant women (n = 507), individuals younger than 20 years 
(n = 13,902), and those with missing data on BPA (n = 23,133) 
and/or sleep-related questions (n = 11,467). The final sample 
consisted of adult non-pregnant 2005–2010 NHANES partici-
pants who were 20 years or older, and had no missing data on 
key variables of interest (n = 5,034).
Variable Definitions
Bisphenol-A Level
Spot urine samples were obtained from a one-third random 
subset of NHANES participants. Total urinary BPA, both 
conjugated and free, was analyzed by online solid-phase ex-
traction coupled to high performance liquid chromatography 
(HPLC)-isotope dilution tandem mass spectrometry by the 
Division of Environmental Health Laboratory Sciences at the 
National Center for Environmental Health, CDC.68 The details 
of quality assurance and quality control procedures, including 
coefficients of variation (CV of 8.1% to 18.6% for the low 
BPA quality control pools and 5.7% to 12.1% for the high BPA 
quality control pools) and lower limits of detection (LLOD/√2 
or 0.28 ng/mL), were described elsewhere.68 After careful ex-
amination of its distributional properties, we analyzed BPA 
level as a loge-transformed continuous variable and in quar-
tiles (< 0.9 ng/mL; 0.9 to < 1.9 ng/mL; 1.9 to < 3.7 ng/mL; 3.7+ 
ng/mL). We used quartiles instead of tertiles or quintiles to 
maximize our ability to detect a relative risk of ~1.3, assuming 
that the proportion having the outcome is 0.1 with α = 0.05 and 
β = 0.2.
Sleep Adequacy
Three questions related to sleep adequacy were available 
in all 3 waves (2005–2006, 2007–2008, and 2009–2010) of 
NHANES data as follows: “How much sleep do you usually 
get at night on weekdays or workdays?” (Q1: Sleep duration), 
“Have you ever told a doctor or other health professionals that 
you have trouble sleeping?”(Q2: Help-seeking behavior for 
sleep problems) and “Have you ever been told by a doctor or 
other health professional that you have a sleep disorder?” (Q3: 
Diagnosis with sleep disorders). Responses to Q1 were mea-
sured on a continuous scale as number of hours, and responses 
to Q2 and Q3 were dichotomous “yes” or “no”76; Q1 was also 
analyzed as a categorical variable using 3 distinct definitions 
based on recent studies of NHANES data, namely: definition 1 
(“short sleep (yes): < 6 h,” “short sleep (no): ≥ 6 h”);43 definition 
2 (“short sleep: < 7 h,” “normal sleep: 7–8 h,” “long sleep: > 8 
h”);76 definition 3 (“very short sleep: < 5 h,” “short sleep: 5–6 
h,” “normal sleep: 7–8 h,” “long sleep: ≥ 9 h”).77
Covariates
Selected demographic, socioeconomic, lifestyle, and health 
characteristics were considered as a priori confounders for 
the hypothesized relationships between BPA level and sleep 
adequacy, based on the literature.42,43,45,74–83 These include sex 
(male, female), age (< 30, 30–39, 40–49, 50–59, 60+ years), 
race/ethnicity (Non-Hispanic White, Non-Hispanic Black, 
Hispanic, Other), education (less than high school, high school, 
more than high school), marital status (married/cohabiting, not 
married), poverty income ratio (continuous; < 100%, 100% 
to < 200%, ≥ 200%), smoking status (Current smoker, Ex-
smoker, Never smoker), alcohol consumption (≥ 12 glasses in 
the past 12 months) (yes/no), body mass index (BMI) (< 25, 25 
to < 30, 30+ kg/m2), waist circumference (High: ≥ 102 cm (40 
in) in men or ≥ 88 cm (35 in) in women vs. Low: < 102 cm (40 
in) in men or < 88 cm (35 in) in women), self-rated health (ex-
cellent/very good/good, fair/poor), depressive symptoms based 
on the 9-item Patient Health Questionnaire (PHQ) total score 
(High: ≥ 10, Low: < 10), and adjusted creatinine level which 
was calculated based on equations described by Silver and co-
workers.68 Of note, the normal creatinine levels are estimated 
to be 0.6 to 1.2 mg/dL in adult males and 0.5 to 1.1 mg/dL in 
adult females.
Statistical Analysis
Statistical analyses were performed using STATA version 12 
(STATA Corporation, College Station, TX). Whereas frequen-
cies and percentages were computed for categorical variables, 
means and standard errors of the mean (SEM) were computed 
for continuous variables. Unadjusted (Model I), age- and sex-
adjusted (Model II) as well as fully adjusted (Model III) models 
were constructed for BPA as a predictor of sleep adequacy, 
using ‘svy:reg’ for continuous outcomes, ‘svy:logit’ for binary 
outcomes and ‘svy:ologit’ for ordinal outcomes. Measures of 
association were presented as beta coefficients with their 95% 
confidence intervals (CI) for linear regression models and odds 
ratios (OR) with their 95% CI for logistic regression models. 
Sampling weights were used to produce correct population 
estimates accounting for differential probabilities of selection 
and adjusting for non-coverage, non-response, and over-sam-
pling of subpopulations. Two-sided statistical tests were per-
formed at an α level of 0.05.
RESULTS
Between 2005 and 2010, 5,034 participants met inclusion cri-
teria in this study; 2,564 were men and 2,470 were women. 
Table 1 details the demographic, socioeconomic, lifestyle, 
and health characteristics of the study participants by sex. 
Overall, the mean (± SEM) for age, BMI, waist circumference, 
depressive symptoms, and adjusted creatinine level were 
47.0 ± 0.35 years, 28.7 ± 0.1 kg/m2, 97.9 ± 0.4 cm, 2.8 ± 0.08, 
and 909614.2 ± 13896.9 mg/dL, respectively. Furthermore, 
24% were ≥ 60 years, 70% were non-Hispanic White, 57% 
had more than high school education, 58% were married, 63% 
had poverty income ratio > 2, 53% never smoked, and 76% 
drank alcohol in the past 12 months. Also, 35% had BMI ≥ 30 
kg/m2, 52% had a high waist circumference, 84% had excel-
lent, very good, or good self-rated health, and 6% had high 
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Table 1—Demographic, socioeconomic, lifestyle and health characteristics of study sample by sex: National Health and Nutrition Examination Surveys 
2005–2010 (n = 5,034).
Total (n = 5,034) Males (n = 2,564) Females (n = 2,470) P value
Age (years) n = 5,034 n = 2,564 n = 2,470
Mean ± SEM 47.0 ± 0.35 45.9 ± 0.5 48.1 ± 0.4 0.001
Categorical 0.03
< 30 18.2 19.9 16.6
30–39 18.2 18.9 17.4
40–49 21.1 20.9 21.3
50–59 18.7 18.6 18.8
≥ 60 23.8 21.6 25.9
Race n = 5,034 n = 2,564 n = 2,470 0.1
White 70.5 70.3 70.7
Black 11.3 10.5 12.1
Hispanic 12.4 13.5 11.4
Other 5.8 5.7 5.9
Education n = 5,028 n = 2,562 n = 2,466 0.5
Less than high school 18.4 19.0 17.9
High school 24.9 24.3 25.5
More than high school 56.6 56.7 56.6
Marital status n = 5,030 n = 2,562 n = 2,468 0.0001
Married 58.3 61.9 54.7
Not married 41.7 38.1 45.3
Poverty income ratio n = 5,025 n = 2,561 n = 2,464 0.0007
< 1 18.5 16.6 20.3
1–2 18.9 18.1 19.7
≥ 2 62.6 65.2 60.0
Smoking status n = 5,030 n = 2,562 n = 2,468  < 0.0001
Current smoker 22.8 24.9 20.7
Ex-smoker 24.8 28.0 21.6
Never smoker 52.5 47.1 57.7
Alcohol (past 12 months) n = 4,608 n = 2,365 n = 2,243  < 0.0001
Yes 76.0 85.6 66.5
No 23.9 14.4 33.5
Body mass index (kg/m2) n = 4,987 n = 2,534 n = 2,453
Mean ± SEM 28.7 ± 0.1 28.8 ± 0.2 28.5 ± 0.2 0.2
Categorical  < 0.0001
< 25 32.0 26.6 37.2
25–30 32.9 38.4 27.8
≥ 30 34.9 34.9 34.9
Waist circumference (cm)* n = 5,034 n = 2,564 n = 2,470
Mean ± SEM 97.9 ± 0.4 101.4 ± 0.5 94.7 ± 0.4  < 0.0001
Categorical  < 0.0001 
High 51.8 43.3 60.0
Low 48.2 56.7 39.9
Self-rated health n = 4,622 n = 2,373 n = 2,249 0.6
Excellent/Very good/Good 83.5 83.8 83.1
Fair/Poor 16.5 16.2 16.9
Depressive symptoms n = 5,034 n = 2,564 n = 2,470 
Mean ± SEM 2.8 ± 0.08 2.3 ± 0.08 3.2 ± 0.1  < 0.0001
Categorical 0.0001
High (≥ 10) 5.9 4.4 7.3
Low (< 10) 94.1 95.6 92.7
Creatinine (mg/dL) – adjusted n = 5,034 n = 2,564 n = 2,470  < 0.0001
Mean ± SEM 909614.2 ± 13896.9 1092170 ± 18177.8 731908.2 ± 18516.82
* “High” refers to waist circumference > 102 cm in males and > 88 cm in females.
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depressive symptoms. All these characteristics differed 
significantly by sex, with the exception of race, education, and 
self-rated health.
BPA levels and sleep adequacy of the study participants 
by sex are presented in Table 2. Overall, the mean (± SEM) 
for BPA level and duration of sleep were 4.2 ± 0.4 ng/mL 
and 6.9 ± 0.03 h, respectively. Furthermore, 87% reported 
sleeping ≥ 6 h, 55% 7 to 8 h, and 7% ≥ 9 h. Moreover, 24% 
reported ever telling a doctor that they had trouble sleeping, 
and only 8% were ever diagnosed with a sleep disorder. All 
these characteristics were significantly different among men 
and women, with the exception of the binary definition (< 6 h 
vs. ≥ 6 h) of sleep duration.
Table 3 presents urinary BPA level as a predictor of sleep 
duration defined as a continuous or categorical variable in 
unadjusted (Model I), sex- and age-adjusted (Model II), and 
fully adjusted (Model III) models. As expected, an inverse 
relationship was observed between sleep duration, defined as 
a continuous variable, and loge-transformed BPA level in all 
three models (Model I: −0.06 [−0.09, −0.02]; Model II: −0.06 
[−0.09, −0.02]; Model III: −0.05 [−0.09, −0.002]). Taking the 
lowest quartile as a referent group, the upper quartile of BPA 
was inversely related to sleep duration, defined as a continuous 
variable, in the unadjusted (β = −0.2, 95% CI: −0.3, −0.03) as 
well as sex- and age-adjusted model (β = −0.2, 95% CI: −0.3, 
−0.03), but not the fully adjusted model (β = −0.12, 95% CI: 
−0.3, 0.02). The categorical definitions 1 (short sleep (yes): < 6 
h, short sleep (no): ≥ 6 h) and 3 (very short sleep: < 5 h, short 
sleep: 5–6 h, normal sleep: 7–8 h, long sleep: ≥ 9 h) for sleep 
duration were inversely and significantly related to loge-trans-
formed BPA level in unadjusted, sex- and age-adjusted and 
fully adjusted models. By contrast, the categorical definition 
2 (short sleep: < 7 h, normal sleep: 7–8 h, long sleep: > 8 h) for 
sleep duration was inversely and significantly related to loge-
transformed BPA level only in the unadjusted and sex- and 
age-adjusted models. When defined as quartiles, BPA level 
was inversely and significantly related to categorical definition 
1 of sleep duration in the unadjusted model as well as categor-
ical definitions 2 and 3 of sleep duration in the unadjusted and 
sex- and age-adjusted models.
Table 4 presents urinary BPA level as a predictor of self-
reported sleep problems in unadjusted, sex- and age-adjusted 
and fully adjusted models. Clearly, only unadjusted models 
yielded significant and positive relationships between having 
told a doctor that he/she had trouble sleeping and urinary BPA 
level defined either as a continuous variable (OR = 1.08, 95% 
CI: 1.01, 1.16) or in quartiles (Q4 vs. Q1: OR = 1.24, 95% CI: 
1.01, 1.52). By contrast, no significant relationship was ob-
served between urinary BPA level and ever being told by a 
doctor that he/she had a sleeping disorder in the 3 models.
Table 2—Urinary bisphenol level and sleep adequacy of study sample by sex: National Health and Nutrition Examination Surveys 2005–2010 
(n = 5,034).
 Total (n = 5,034) Males (n = 2,564) Females (n = 2,470) P value
Bisphenol-A (ng/ml) n = 5,034 n = 2,564 n = 2,470
Mean ± SEM 4.2 ± 0.4 4.4 ± 0.5 4.0 ± 0.4  < 0.0001 †
Quartiles 0.0001
< 0.9 23.3 19.4 27.1
0.9–1.9 26.1 27.0 25.2
1.9–3.7 25.9 28.3 23.6
≥ 3.7 24.7 25.3 24.2
Sleep duration n = 5,023 n = 2,560 n = 2,463
Mean ± SEM 6.9 ± 0.03 6.8 ± 0.03 6.9 ± 0.03 0.002
Categorical 1 n = 5,023 n = 2,560 n = 2,463 0.11
< 6 12.8 13.8 11.8
≥ 6 87.2 86.2 88.2
Categorical 2 n = 5,023 n = 2,560 n = 2,463 0.001
< 7 37.9 39.3 36.6
7–8 55.3 55.3 55.3
> 8 6.8 5.4 8.1
Categorical 3 n = 5,023 n = 2,560 n = 2,463 0.004
< 5 4.6 4.7 4.4
5–6 33.3 34.6 32.2
7–8 55.3 55.3 55.3
≥ 9 6.8 5.4 8.1
Ever told doctor had trouble sleeping n = 5,029 n = 2,561 n = 2,468  < 0.0001
Yes 24.2 19.9 28.3
No 75.8 80.1 71.7
Ever told by doctor had sleeping disorder n = 5,026 n = 2,558 n = 2,468 0.03
Yes 7.7 8.8 6.6
No 92.3 91.2 93.4
†Log-transformed values were compared according to sex. 
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DISCUSSION
In this cross-sectional study, we investigated whether BPA was 
associated with sleep adequacy in a nationally representative 
sample of U.S. adults in whom self-reported sleep duration, 
help-seeking behavior for sleep problems, and diagnosis with 
sleep disorders were considered as the main outcomes of in-
terest. Consistent with our hypotheses, the results indicated 
that loge-transformed BPA level was inversely related to sleep 
duration defined, in hours as a continuous variable, a dichoto-
mous variable (≥ 6 vs. < 6) or an ordinal variable (≥ 9, 7–8, 
5–6, < 5), after adjustment for confounders. By contrast, help-
seeking behavior for sleep problems and diagnosis with sleep 
disorders were not significantly associated with loge-trans-
formed BPA level in the fully adjusted models. Also, when 
BPA level was defined in quartiles, its relationship with sleep 
adequacy did not reach statistical significance after controlling 
for demographic, lifestyle, and health characteristics of the 
study sample. The latter finding suggests a complex nonlinear 
relationship between BPA and indicators of sleep adequacy.
Emerging evidence suggests that BPA, atrazine, dichloro-
diphenyltrichloroethane, diethylstilbestrol, dioxin, phthalates, 
polychlorinated biphenyls, organotins, and other endocrine 
disruptors may have negative health effects.84–91 Endocrine dis-
ruptors are lipophilic substances that usually act as transcrip-
tion factors for nuclear hormone receptor superfamily and can 
either mimic or block the action of endogenous sex hormones, 
resulting in irreversible alterations or reversible alterations in 
patterns of gene expression.84,86–91 Sex steroids (androgens and 
estrogens) play an important role in establishing and main-
taining adipose tissue84,85 and in conjunction with growth hor-
mones can mobilize lipids and have anti-adipogenic effects; 
their effects are counteracted by insulin and cortisol that have 
Table 3—Urinary bisphenol level as a predictor of sleep duration defined as a continuous or categorical variable.
Model I: Unadjusted Model II: Age-and-Sex Adjusted Model III: Fully Adjusted
Sleep duration (hours) – Continuous β (95% CI) β (95% CI) β (95% CI)
Urinary bisphenol level (ng/mL) – Continuous −0.06 (−0.09, −0.02) −0.06 (−0.09, −0.02) −0.05 (−0.09, −0.002)
Urinary bisphenol level (ng/mL) – Quartiles P = 0.007 P = 0.006 P = 0.1
< 0.9 Ref. Ref. Ref.
0.9–1.9 −0.05 (−0.18, 0.08) −0.05 (−0.18, 0.09) −0.08 (−0.2, 0.06)
1.9–3.7 −0.1 (−0.3, −0.01) −0.1 (−0.2, 0.008) −0.09 (−0.2, 0.04)
≥ 3.7 −0.2 (−0.3, −0.03) −0.2 (−0.3, −0.03) −0.12 (−0.3, 0.02)
Hours of sleep – Categorical 1 OR (95% CI) OR (95% CI) OR (95% CI) 
Urinary bisphenol level (ng/mL) – Continuous 0.87 (0.79, 0.94) 0.87 (0.79, 0.95) 0.88 (0.79, 0.98)
Urinary bisphenol level (ng/mL) – Quartiles P = 0.02 P = 0.03 P = 0.1
< 0.9 Ref. Ref. Ref.
0.9–1.9 1.03 (0.78, 1.36) 1.04 (0.79, 1.38) 0.94 (0.70, 1.26)
1.9–3.7 0.77 (0.57, 1.04) 0.79 (0.58, 1.08) 0.79 (0.57, 1.11)
≥ 3.7 0.73 (0.53, 0.99) 0.73 (0.52, 1.02) 0.76 (0.52, 1.11)
Model I: Unadjusted Model II: Age-and-Sex Adjusted Model III: Fully Adjusted*
Sleep duration (hours) – Categorical 2 OR (95% CI) OR (95% CI) OR (95% CI) 
Urinary bisphenol level (ng/mL) – Continuous 0.93 (0.88, 0.98) 0.93 (0.88, 0.98) 0.97 (0.91, 1.03)
Urinary bisphenol level (ng/mL) – Quartiles P < 0.0001 P = 0.02 P = 0.44
< 0.9 Ref. Ref. Ref. 
0.9–1.9 0.88 (0.69, 1.12) 0.88 (0.69, 1.12) 0.85 (0.65, 1.12)
1.9–3.7 0.91 (0.73, 1.13) 0.91 (0.73, 1.14) 0.99 (0.75, 1.32)
≥ 3.7 0.77 (0.63, 0.93) 0.77 (0.63, 0.93) 0.86 (0.68, 1.08)
Sleep duration (h) – Categorical 3 OR (95% CI) OR (95% CI) OR (95% CI) 
Urinary bisphenol level (ng/mL) – Continuous 0.81 (0.70, 0.93) 0.78 (0.67, 0.91) 0.79 (0.67, 0.94)
Urinary bisphenol level (ng/mL) – Quartiles P = 0.03 P = 0.02 P = 0.06
< 0.9 Ref. Ref. Ref.
0.9–1.9 0.98 (0.57, 1.69) 0.94 (0.55, 1.62) 0.92 (0.49, 1.75)
1.9–3.7 0.71 (0.42, 1.19) 0.65 (0.38, 1.13) 0.69 (0.39, 1.22)
≥ 3.7 0.62 (0.39, 0.99) 0.56 (0.34, 0.93) 0.63 (0.35, 1.12)
*Adjusted for sex (male, female), age (< 30, 30–39, 40–49, 50–59, ≥ 60 years), race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, 
Other), education (less than high school, high school, more than high school), marital status (married/cohabiting, not married), poverty income ratio 
(continuous; < 100%, 100%–200%, ≥ 200%), smoking status (current smoker, ex-smoker, never smoker), alcohol consumption (at least 12 glasses in the 
past 12 months) (yes, no), body mass index (BMI) (< 25, 25–30, ≥ 30 kg/m2), waist circumference (High: ≥ 102 cm (40 in) in men or ≥ 88 cm (35 in) in women 
vs. Low: < 102 cm (40 in) in men or < 88 cm (35 in) in women), self-rated health (excellent/very good/good, fair/poor), depressive symptoms based on the 
9-item Patient Health Questionnaire (PHQ) total score (high: ≥ 10, low: < 10) and adjusted creatinine level.
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adipogenic effects.84 Exposure to endocrine disruptors such 
as BPA is thought to promote adiposity typical of Cushing 
syndrome, polycystic ovary syndrome, growth hormone defi-
ciency, menopause, aging, alcoholism, and depression.84,88
Since the 1960s, BPA has been produced in large quantities 
for the manufacturing of flame retardants, dental sealants and 
fillings, adhesives, protective coatings, infant feeding bottles, 
food and mineral water storage containers, and food and bev-
erage can linings.84,92–98 Although studies have suggested that 
low-dose BPA exposure may be associated with increased 
reproductive and cancer risks,99–105 regulatory bodies in the 
U.S., Canada, and Europe have distinct views on whether BPA 
should be considered a hazardous substance.106
So far, a limited number of studies have used a nationally 
representative sample to investigate health effects of BPA, and 
several of these studies, most of which used NHANES data, 
have linked high BPA to obesity-related cardiometabolic risk 
factors and conditions.69,92,93,107–109 The finding of an inverse re-
lationship between sleep duration and BPA level is consistent 
with the current evidence that BPA is a chemical substance 
that has the capacity to bind nuclear and membrane surface 
estrogen receptors, resulting in obesity-related disturbances 
which can potentially mediate suboptimal sleep.58,59,64,66,69 
However, our results also suggest that BPA level may be nega-
tively associated with sleep duration, independently of BMI 
or waist circumference, both of which are indices of obesity-
related disturbances. Therefore, it is also plausible that BPA 
may have an adverse impact on muscular function in the upper 
airway, causing sleep disorders such as OSA, as suggested by 
biomedical researchers.41 In-depth analyses are needed to eval-
uate the mediating role of obesity-related cardiometabolic risk 
factors and conditions, including components of the metabolic 
syndrome, in the observed relationship between BPA and sleep 
duration. While the proposed biological mechanisms are plau-
sible, reverse causality cannot be ruled out as a potential expla-
nation for the observed associations. In fact, it is also plausible 
that individuals who experience shorter sleep are more likely 
to experience environmental BPA exposure which, in turn, as-
sumes a state of wakefulness.
To our knowledge, this is the first study examining whether 
BPA may be causally or non-causally linked to adequacy of 
sleep in a nationally representative sample of U.S. adults. Pre-
vious studies have used NHANES data to examine correlates 
of sleep, including race/ethnicity,43,83 socioeconomic status,83 
eating behaviors,80 nutritional biomarkers,77,79 alcohol use,74 
obesity,76 pre-diabetes,78 diabetes,76 hypertension,82 homocys-
teine,45 inflammatory biomarkers,43,81 cardiovascular disease,42 
anxiety,75 and functional health.43 In a recent study, Erden and 
colleagues41 evaluated the associations among OSA, BPA, vi-
tamin D, and parathyroid hormone levels using a sample of 
128 subjects who had undergone polysomnography and were 
classified as control (n = 43), moderate OSA (n = 23), or se-
vere OSA (n = 62).41 Consistent with our findings, their results 
indicated that while vitamin D level was lower in both OSA 
groups and PTH was higher in OSA groups than in the control 
subjects, and BPA levels were higher in severe OSA than mod-
erate OSA and controls.41
Nevertheless, our findings should be interpreted with cau-
tion and in light of several limitations. First, the study design is 
cross-sectional, which precludes establishing cause-and-effect 
relationships among variables under study. Second, analyses 
were based on previously collected data reducing flexibility in 
the definition of outcome, exposure, and covariate variables. 
Third, BPA metabolites were assessed by a single assay in 
Table 4—Urinary bisphenol level as a predictor of self-reported sleep problems.
Model I: Unadjusted Model II: Age-and-Sex Adjusted Model III: Fully Adjusted*
Ever told doctor had trouble sleeping OR (95% CI) OR (95% CI) OR (95% CI) 
Urinary bisphenol level (ng/mL) – Continuous 1.08 (1.01, 1.16) 1.03 (0.96, 1.11) 1.08 (0.99, 1.19)
Urinary bisphenol level (ng/mL) – Quartiles P = 0.1 P = 0.9 P = 0.4
< 0.9 Ref. Ref. Ref.
0.9–1.9 1.19 (0.94, 1.52) 1.08 (0.85, 1.39) 1.13 (0.86, 1.49)
1.9–3.7 1.11 (0.88, 1.39) 0.96 (0.75, 1.22) 1.03 (0.77, 1.39)
≥ 3.7 1.24 (1.01, 1.52) 1.06 (0.85, 1.34) 1.19 (0.89, 1.59)
Ever told by doctor had sleeping disorder OR (95% CI) OR (95% CI) OR (95% CI) 
Urinary bisphenol level (ng/mL) – Continuous 1.02 (0.89, 1.16) 0.98 (0.86, 1.12) 1.05 (0.89, 1.24)
Urinary bisphenol level (ng/mL) – Quartiles P = 0.9 P = 0.6 P = 0.8
< 0.9 Ref. Ref. Ref.
0.9–1.9 1.01 (0.66, 1.54) 0.98 (0.63, 1.52) 1.18 (0.74, 1.88)
1.9–3.7 0.85 (0.56, 1.28) 0.79 (0.51, 1.22) 0.95 (0.58, 1.57)
≥ 3.7 1.09 (0.72, 1.67) 0.97 (0.62, 1.52) 1.18 (0.71, 1.98)
*Adjusted for sex (male, female), age (< 30, 30–39, 40–49, 50–59, ≥ 60 years), race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, 
Other), education (less than high school, high school, more than high school), marital status (married/cohabiting, not married), poverty income ratio 
(continuous; < 100%, 100%–200%, ≥ 200%), smoking status (current smoker, ex-smoker, never smoker), alcohol consumption (at least 12 glasses in the 
past 12 months) (yes, no), body mass index (BMI) (< 25, 25–30, ≥ 30 kg/m2), waist circumference (high: ≥ 102 cm (40 in) in men or ≥ 88 cm (35 in) in women 
vs. low: < 102 cm (40 in) in men or < 88 cm (35 in) in women), self-rated health (excellent/very good/good, fair/poor), depressive symptoms based on the 
9-item Patient Health Questionnaire (PHQ) total score (high: ≥ 10, low: < 10) and adjusted creatinine level.
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NHANES, which may not represent diurnal changes in BPA 
levels. Fourth, the study sample was selected on the basis of 
availability of exposure and outcome data, which may have 
resulted in selection bias. In particular, the inclusion and ex-
clusion criteria that define the selected subset of NHANES 
2005–2010 subjects may have influenced the effectiveness of 
weighting variables. Further analyses suggested that the se-
lected and non-selected adult subjects differed significantly 
on sex, age, race/ethnicity, and education. Fifth, NHANES 
assessed adequacy of sleep using self-report rather than poly-
somnography or medical records data, which may have led to 
non-differential misclassification of the outcome variables of 
interest, potentially biasing measures of association towards 
the null value. Moreover, the question pertaining to sleep dura-
tion was limited in scope as it only considered week or work-
days. Considering the existence of sleep compensation (short 
sleep during week or workdays and longer sleep on weekends 
or free days), the general sleep time is underestimated. Also, 
at least one of the sleep-related outcomes is a rare event with a 
prevalence of less than 10%, reducing our ability to detect an 
association with BPA exposure.
Sixth, although numerous covariates were included in the 
multivariable models, we cannot rule out residual confounding 
as an explanation for the observed associations due to un-
controlled factors such as area of residence and diet quality. 
Seventh, although sex differences were observed, we could 
not conduct stratified analyses according to sex as a result of 
sample size limitations. Finally, our findings can only be gener-
alized to adult men and women, and further research is needed 
to evaluate these relationships in adolescents and children.
In conclusion, secondary analyses of 2005–2010 NHANES 
data involving U.S. adults suggests that sleep duration, but not 
help-seeking behaviors related to poor sleep, may be inversely 
related to BPA level, with implications for primary and sec-
ondary prevention. Regulation of environmental BPA level 
could potentially reduce the risk of adverse health outcomes, 
including poor sleep. Also, monitoring of BPA level by health-
care professionals could help identify patients at high risk for 
poor sleep and aid in the management of patients experiencing 
poor sleep. Our results support the idea that excessively high 
levels of BPA may, directly or indirectly, be linked to poor 
sleep. Further research is needed to better understand what 
specific environmental exposures may have led to excessive 
levels of BPA and consequently adverse outcomes such as in-
adequate sleep.
ABBREVIATIONS
BMI, body mass index
BPA, Bisphenol-A
CDC, Centers for Disease Control and Prevention
CI, confidence interval
CV, coefficient of variation
HPLC, high performance liquid chromatography
LLOD, lower limit of detection
NHANES, National Health and Nutrition Examination 
Surveys
OR, odds ratio
OSA, obstructive sleep apnea
PHQ, Patient Health Questionnaire
SEM, standard error of the mean
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